Last updated: 2026-09-16 10:32:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Tenaya Therapeutics, Inc. (TNYA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.68, with a market capitalisation of $155.37M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.53 to $2.35. This page covers its latest market performance, valuation, price trends and company information.
$155.37M | |
$0.68 | |
$32.00 | |
$0.36 | |
$0.67 | |
505.00 | |
2.13M | |
-- | |
$2.35 | |
$0.53 | |
-- | |
-- |
Tenaya Therapeutics, Inc. (TNYA) is trading at $0.68 in pre-market trading as of 2026-09-16 10:31:00, up 0.97% ($0.01) from the previous close of $0.67
Pre-market trading shows how investors are pricing TNYA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Tenaya Therapeutics, Inc. (TNYA) moved from $0.68 to $0.68, representing a decline of 0.91% ($0.01).
The stock traded between $0.64 and $0.71 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.90 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.0%
TNYA is currently trading at $0.68, placing it 8.0% of the way from its 52-week low of $0.53 to its 52-week high of $2.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 70 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tenaya Therapeutics, Inc. (TNYA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.